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Acute upper gastrointestinal lesions have a multifactorial etiology but, regardless of the cause,
they are related to mucosal barrier destruction. Since Helicobacter pylori induces a superficial
chronic gastritis with the infiltration of neutrophils in the mucosa, it was speculated that Helicobacter
pylori infection could also cause bleeding lesions. The diagnosis, the proper treatment and the
revaluation of its effectiveness actually represent the prophylaxis of some diseases such as peptic
ulcer, gastric lymphoma or mucosa-associated lymphoid tissue (MALT) and gastric cancer. These
diseases and their severe complications are life-threatening for the patient. Periodic renewal of the
treatment and knowing the real causes of Helicobacter pylori resistance to various antibiotics must
always be understood by the clinician. Although Helicobacter pylori treatment fails in about 20% of
cases, moral support of the patient by the clinician, information about possible evolutional
complications of Helicobacter pylori infection, and periodic evaluation of the patient during therapy,
are important tools on which the therapeutic success depends.
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Introduction

Morphology

Helicobacter pylori bacterium (H. pylory) is

H. pylori is a gram negative bacterium,

the first officially recognized carcinogen. Over half measuring 2 to 4 pm in length and 0.5 to 1 pm in
the world's population is colonized with this width. The body has 2 to 6 flagella and the motility
bacterium, being the best known gram negative of the flagella confers and allows rapid movement
changes in viscous solutions, such as the mucus layer of the
induced gastric mucosam, the Helicobacter pylori gastric epithelial cell (6). Unlike many other
gastrointestinal tract pathogens, Helicobacter pylori
infection represents a determining factor in the
does not have fimbriae adhesins. The growth occurs
occurrence of the gastrointestinal disease that can
at a temperature of 34 - 40° C, with an optimum of
range from chronic gastritis without clinical
37º C. Although its natural habitat is the acid gastric
symptoms to serious neoplastic diseases. In many
mucosa, H. pylori is considered to be a neutrophil.
cases, the clinical signs of upper gastrointestinal
The bacterium survives to pH < 4 exposure, but the
bleeding is the first symptom of gastrointestinal
growth occurs only in relatively narrow pH range of
infection with Helicobacter pylori.The disease is the
5.5 to 8.0, with optimal growth at neutral pH (7, 8).
result of complex interactions between host and
Geographical distribution
bacteria (1).
bacteria.

Because

histopathological

History

A high diversity in prevalence of H. pylori
infection among adults in Europe was registered in

Barry Marshall and Robin Warren were first
to describe the isolation and culture of a bacterium
in the human stomach, later known as H. pylori (2).
Their experiments on themselves using selfingestion (3, 4) and those on volunteers showed
that bacteria can colonize the human stomach and
can induce inflammation of the stomach mucosa
(5).

2000, with a global prevalence in adulthood of
18.3-82.5%, with variations from country to
country. The highest prevalence, 82.5% for adults
older than 18 years old, was measured in Turkey,
on a nationally representative population; and the
lowest prevalence, 18,3%, was found in Denmark
(9). H. pylori prevalence shows large geographical
variations. In various developing countries, more

Later research has shown that colonization of than 80% of the population is H. pylori positive,
H. pylori can cause chronic gastritis, peptic ulcers, even at young ages. H. pylori prevalence in
as well as gastric lymphoma mucosa associated industrialized countries remains generally below
lymphoid tissue (MALT) or gastric cancer.

40% and is significantly lower in children than in
151
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adults and the elderly. In geographical areas, the frequently appears in the antrum and gastric body
prevalence of H. pylori correlates inversely with with mononuclear and neutrophil cells. Active
socioeconomic status, particularly regarding living chronic gastritis is the main condition linked to the
conditions during childhood (10).

colonization with H. pylori, and other disorders

H. pylori colonization is not a disease itself,
but it influences the relative risk of developing
different clinical conditions of the gastrointestinal

associated with H. pylori results in particular
because of the chronic inflammatory process (1).
Causes of gastritis, other than H. pylori

tract and possibly the hepatobiliary tract. Therefore, infection are: excessive consumption of alcohol and
routine or random testing for H. pylori

has no nonsteroidal antiinflammatory drugs (NSAIDs),

benefit, but testing should be performed in order to cytomegalovirus infections, and chronic idiopathic
find the cause of diseases such as peptic ulcer, or, diseases (Crohn's disease and pernicious anemia).
for the prevention of diseases, such as in subjects

Gastric and duodenal ulcers (commonly

with family history of gastric cancer. In these cases, referred to as peptic ulcers) are defined as mucosal
a positive test result justifies a treatment and a defects with a diameter of at least 0.5 cm
negative result may indicate the need to search for penetrating the mucous and/or muscular tunica.
other etiological factors and preventive measures. Gastric ulcers occur mainly along the lesser
For these reasons, a correct understanding of curvature of the stomach, particularly in the mucosa
disorders associated with H. piloryis needed.

in the lining of the boundary between the body and
antrum (1), the duodenum being the most exposed

Types of diseases
Gastritis lesions occur in all

area to gastric acid.
H. pylori

infected subjects, but only a minority develop
clinical signs of this colonization. It is estimated
that H. pylori positive patients have a risk of 1020% of developing peptic ulcer and 1-2% of them
have a risk of developing gastric cancer (11, 12,
13). The emergence of these disorders depends on
the type and severity of gastritis.

The initial worldwide reports, in the first
decade after discovering H. pylori, associated this
infection with about 95% of duodenal ulcers and
85% of gastric ulcers (14). H.pylori eradication has
changed the natural history of ulcer disease and
ulcer recurrence was prevented almost completely
(15). These data show that gastric and duodenal
ulcers seem to be strongly

linked by H. pylori

In acute and chronic gastritis, due to H. pylori infection. However, recurrent ulcers can be
infection, the infiltration of gastric mucosa most registered after H. pylori eradication therapy
152
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because of the persistence or reinfection with H. necessary to decrease the acid secretion and
pylori, NSAID use, or in case of idiopathic ulcer.

antibacterial therapy in H. pylori-positive patients.

The most common complication of ulcer is Chronic ulcer, especially in the pyloric and bulbar
bleeding and perforation, followed by stomach regions, can lead to hypertrophic scars and stenosis,
obstruction. It is estimated that 15-20% of peptic impairing the gastric eviction process. In these
ulcers are complicated by hemorrhage and that patients, malignancy as a cause of obstruction must
approximately 40% of patients who develop upper first be ruled out. Most benign obstructions
gastrointestinal bleeding are also suffering of ulcer associated with H. pylori respond well to the
(1).

eradication therapy, due to the reduction or
The primary treatment for bleeding in

ulcerous disease is endoscopic therapy, which is
mandatory in order to establish the bleeding cause,
to estimate its gravity, and to reduce the risk of

disappearance of inflammation and edema. In
refractory patients, local reconstruction surgery, or
a distal gastric resection is mandatory (1).
Atrophic gastritis, intestinal metaplasia and

recurrent bleeding. H. pylori eradication markedly gastric inflammation, cancer.
reduces the risk of ulcer as wekk as the risk of re-

In histopathogic terms, in chronic gastritis

bleeding for those patients whose bleeding was induced by H. Pylori, studies have shown a loss of
caused by H. pylori infection (16). In general, a the normal architecture through the destruction of
small percentage of bleeding ulcers requires very the gastric mucosa and gastric glands, with normal
careful management, and the indications for mucosa replaced by areas of fibrosis and intestinal
emergency surgery in such cases are: hemodynamic epithelium. These changes occur in areas of the
instability,
hemostasis,

failure

in

performing

endoscopic gastric

and bleeding recurrences

or

duoudenal

mucosa,

with

that

despite inflammation being more severe in 50% of subjects

endoscopic attempts to stop it. Regarding the third aproximativ H. pylori positive (18). The risk of
indication, many doctors indicate surgery after two atrophic gastritis depends on the distribution and
failed endoscopic attempts to stop the bleeding (17). the chronic active inflammation model; therefore,
Several studies have shown that some perforated subjects with decreasing acid production show a
peptic ulcers can be treated conservatively, but in faster progression to atrophic gastritis (19).
any patient with a perforated peptic ulcer, showing

Various studies have shown that H. pylori

peritoneal signs, surgery is required, and then it is positive subjects have increased risk of developing
153
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gastric cancer compared to uninfected persons by residual disease, while the rest show no response
sequence of atrophy and metaplasia (20). This idea (1).
is supported by studies showing links between
geographic prevalenceof H. pylori and incidence of
stomach cancer (21). Factors that influence the
occurrence of gastric atrophy and later, of stomach
cancer in H. pylori positive subjects are both linked
to host and bacteria, by the severity of chronic
inflammatory response caused by them. Therefore,
the risk of developing gastric atrophy is increased in
subjects with strains CagA positive (22), but also in
those with a genetic predisposition to high yields of
IL-1, as a result of the response to the colonization

There have been cases where the disease
evolution depends on the correct guided therapy for
H.pilory. For example, two subjects from the same
family colonized with H. pyloriwho manifested
clinical signs of disease and had positive laboratory
tests (the mucosal lesions are highlighted by upper
gastrointestinal endoscopy). One of them received
the correct treatment to eradicate H. Pylori and had
symptoms remission, while the other, who did not
receive treatment, developed a hemorrhagic MALT
lymphoma 10 years after the diagnosis.

of the bacteria (23).
Diagnose: specificity and sensitivity. Invasive
Although lymphoid tissue is not normally and/ or non-invasive tests.
present in the gastric mucosa, MALT almost always
occurs in response to infection with H. pylori. This
tissue may give birth to a population of B
monoclonal cells from which can proliferate and
form a MALT lymphoma. Almost all patients with
a MALT lymphoma are H. pylori-positive (24) and
H. pylori positive subjects have a significantly
increased risk of developing gastric MALT
lymphoma (25). Different series of "case-reports"

Various tests have been developed for H.
Pylori

detection,

each

with

advantages

and

disadvantages. The available tests are generally
divided into invasive tests, based on gastric
specimens

for

techniques and

histology,

culture,

or

other

non-invasive tests, based on

peripheric evidence, such as blood samples,
respiratory tests, feces, urine or saliva for antibodies
or bacterial antigens detection.

have shown that H. pylori eradication may lead to
complete remission in patients with MALT
lymphoma stage IE confined to the stomach (26,

Invasive methods:
1. The histological methods are the "gold

27). Generally, about 60 to 80% of these patients standard" for diagnosing H. pylori infection,
achieve

complete

remission

after

H.

pylori providing

information

not

only

about

the

eradication, about 10% continue to have signs of inflammation, but also the degree of atrophy
154
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induced by the bacteria. The need for an

3. Serology (with a sensitivity of 80-90%), is

experienced pathologist and the invasive method mainly used for epidemiological studies; it cannot
represent a disadvantage. It has a higher sensitivity verify the evolving infection due to immunologic
and specificity of about 95%.
2. Helicobacter pylori cultures are the

memory.
Invasive methods cause discomfort in patients

alternative to the "gold standard"; with similar during diagnosis, the reason many patients refuse
specificity and sensitivity, they also allow testing upper gastrointestinal endoscopy, especially during
for antimicrobial susceptibility.
3. The rapid urease test is used for the
qualitative detection of Helicobacter pylori in the
urease from the biopsy sample obtained after
gastroscopy. With a specificity and sensitivity of
more than 90% and with good cost-effectivness, the
urease test is a quick method of diagnosis (3
minutes), being the most common invasive method.

the check-up performed 4 weeks after treatment.
Non-invasive

methods

of

diagnosis

are

recommended as an alternative for patients under
45 years of age who do not show symptoms such
as: unexplained weight loss, digestive bleeding or
repeated vomiting. Patients experiencing these
symptoms require upper gastrointestinal endoscopy.
When patients present acute gastroesophageal

It requires an additional test to confirm H. pylori bleeding or are under treatment with proton pump
infection.
Non-invasive methods.

inhibitors, histamine antagonists or antibiotics, most
diagnostic tests for H. pylori infection may show
false negative results. Because of this, it is

1. Testing the urea in the exhaled air is an mandatory that the treatment with inhibitors of
alternative to the "gold standard" with a similar proton pump or histamine antagonists should be
specificity and sensitivity, the most accurate non- stopped two weeks before the diagnosis test, and if
invasive method of diagnosis. It is also a reliable the patients are receiving antibiotic treatment, it
test to evaluate the success of H. pylori eradication should be discontinued at least four weeks before
therapy. The major disadvantage is the high cost of testing (28).
the equipment.

Blood presence in the gastric lumen can lead

2. Antigen testing in stool samples, with a to false results due to the buffering effect it has on
sensitivity greater than 90%, gas not been used the gastric pH. If there is upper gastrointestinal
widely, but it can be reliable for assessing the bleeding or extended mucosal atrophy, serological
success of H. pylori eradication treatment.

tests can be useful, as they indicate a history of
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exposure to H. pylori, although they do not confirm Therapy control
the presence of infection; so, it is necessary to
repeat a non-invasive diagnostic test (if the initial
test result was negative) 4-8 weeks after the
hemorrhagic event (28).
Treatment
Helicobacter pylori eradication methods have

Because treatment of H. pylori fails for
approximately 20% of cases for any number of
different reasons, verifying eradication of infection
after treatment is required in patients at risk. The
same control is mandatory in patients with peptic
ulcers, with MALT, and if patients whose dyspeptic

continued to evolve over the last 20 years. symptoms are persistent. For efficacy evaluation of
Originally, the treatment used H-2 histamine the treatment, 13 C marked urea or feces antigen
receptor antagonists and an antibiotic with a success tests are reccomended. Testing of urea in the
rate of 73-84% (29). In time, this therapy has been patient's exhaled air has a precision higher than the
used less frequently, thanks to new treatment antigen in feces and is preferred in these cases (28).
regimens having much better results. Currently,

Causes of treatment failure

triple therapy based on proton pump inhibitors is
the most commonly used method. This system

1. Antibiotic resistance of Helicobacter pylori

includes the use of PPIs in combination with strains.
amoxicillin and clarithromycin.
Eradication therapy
1.The PPI-based triple therapy consists of
Esomeprazole 20 mg twice a day, or 20 mg of

Diabetes can be a risk factor for resistance to
antibiotics used for Helicobacter pylori eradication.
Although in a study in Taiwan, a better rate of H.
pylori eradication in patients with diabetes was
observed (31), several studies have shown opposite

omeprazole twice a day, Amoxicillin 1 g twice a
results. Impaired microvascular gastric absorption
day and Clarithromycin 500 mg twice a day. The
lowering drugs, gastroparesis and the use of
treatment must be taken for 7 days; this therapy is
highly recommended in Australian guidelines (30).

antibiotics for recurrent urogenital infections,
respiratory infections, and skin resistance represent

2.The quadruple therapy includes Omeprazole the main causes of H. pylori resistance to standard
20mg per day subsalicylate 120 mg four times a treatment in patients with diabetes. Diabetic
day, metronidazole 400 mg three times a day, gastroparesis affects approximately 40% of patients
tetracycline 500 mg four times. The treatment is with diabetes type 1 and 30% of patients with
prescribed between 7 and 14 days (30).

diabetes type 2, especially those with long-term
156
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illness. In a study published by Ojetti et al. (32), H. pylori not only to quinolones and macrolides, but
pylori eradication rate is lower in diabetic adults also to other antibiotics, and thus the rehabilitation
than in children, probably due to more frequent of the treatment strategies where the tests of
infections and antibiotic therapies. Bismuth-based sensitivity of H .pylori strains, isolated from the
therapy has better results for H. pylori eradication patient, are not available.
in these patients, compared with the triple therapy
(33).

H. pylori strains that grow in the presence of
cholesterol are more resistant to multiple antibiotics

The

treatment

of

recurrent

respiratory (35). The antibiotics with this kind of resistance

infections or urogenital tract, often treated with from the patients, in relation with cholesterol, are
antibiotics, is another cause of bacteria resistance to included in some treatment schemes used for to
the drugs used in different regimens for H. pylori treat H. pylori infections, with recent work showing
eradication. Amoxicillin, clarithromycin, metro- that H. pylori has a resistance dependent on bile
nidazole and tetracycline are antibiotics used in salts cholesterol (36). This suggests that H. pylori
first-line treatment of various respiratory or can use the cholesterol modifying its envelope so as
urogenital tract infections; in many cases, patients to resist to multiple antibiotics (37).
undergoing treatment for H. pylori eradication have
used these antibiotics regimen for treating other
infections.

Clarithromycin and tetracycline are antibiotics
which inhibit protein synthesis and are used to treat
H. pylori infection. A study based on the effect of

Increased resistance to levofloxacin in several
European countries is also worrying because it
opposes its use of empirical anti-H pylori treatment
regimens without prior sensitivity tests (34). In the

antibiotics on the viability of H. pylori cultivated in
the presence or absence of cholesterol showed how
cholesterol

substantially

increased

H.

pylori

resistance to tetracyclin and clarithromycin.

same study published by Megraud F, a significant
positive association was shown between the use of

Ciprofloxacin and Metronidazole inhibit the

antibiotics in the ambulatory and the primary DNA replication, and they are also used for the
degree of resistance observed in antimicrobial key treatment of H. pylori infections. However, H.
agents used for the eradication of H pylori. pylori grown with cholesterol was more resistant to
Knowledge about the antibiotics used in a particular ciprofloxacin than H. pylori

grown without

region or by every patient can provide information cholesterol. H. pylori grown with cholesterol
regarding the sensitivity or the resistance of H showed

a

modest

increase

resistance

to
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metronidazole (about 10 to 30 times). For Conclusions
antibiotics that inhibit the biosynthesis of the cell

Helicobacter pylori infection is still a global

wall, i.e., ampicillin and amoxicillin, there were concern, its diagnosis and

treatment may raise

similar results: H. pylori strains grown on the serious challenges. The diagnosis, the effective
medium with cholesterol levels were up to 1,000 treatment and the revaluation of its effectiveness
times more resistant to antibiotics than those grown represents the prophylaxis of some diseases such as
without cholesterol. Bismuth compounds are part of peptic

ulcer,

gastric

lymphoma

of

mucosa-

the regimen of H. pylori infection in some associated lymphoid tissue (MALT) and gastric
countries. H. pylori cultivated with cholesterol was cancer.

These

diseases

and

their

severe

significantly more resistant to bismuth (up to 107), complications (bleeding, perforation) are lifethan H. pylori bacteria grown without cholesterol. threatening for the patient. Treatment failure is due
H. pylori grown without cholesterol was also more to the patient’s non-cooperation or his/her
susceptible to rifampicin than H. pylori grown with

resistance to antibiotics; it varies depending on the
patient’s country of origin, the patient him/herself,

cholesterol (35).

and previous prescriptions of antibiotics for other
2.Patient non-cooperation. Quitting the initial conditions. If the second treatment (as
treatment.
recommended by regional doctors) also fails, an
Many patients abandon treatment and the endoscopy is required in order to have a biopsy
therapeutic scheme after being diagnosed with H. sample from which to perform culture and DST.
reasons: Although H. pylori treatment fails in about 20% of
improvement and disappearance of symptoms of cases, moral support for the patient by the clinician,
information
about
possible
evolutional
peptic ulcer; or the side effects of the treatment. The
complications of H. pylori infection, and periodic
recurrence of symptoms at some time after giving
evaluation of the patient during therapy, are
up the initial treatment requires H. pylori culture,
important tools on which the therapeutic success
allowing thus antimicrobial susceptibility testing.
depends.
The patient's support by the clinician about the
pylori

infection,

typically

for

two

awareness of the disease, information about the Acknowledgment:
possible complications of this disease, and periodic
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